Joshua T. Brumm

Joshua T. Brumm, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Dyne Therapeutics, Inc., Crescent Biopharma, Inc. and Aravive, Inc. Over a trading history stretching from 30 December 2015 to 18 September 2026, the count stands at 27 filings.

Sales make up the whole of the open-market record (11 sales, €774k). The amount is not disclosed for 2 filings. Outside the open market, there are 6 share grants and 4 option exercises. Since January 2026: no purchases and 3 sales on the market.

Most recently, on 18 September 2026, the filings show an open-market sale worth €25k in Crescent Biopharma, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.